Details

Autor(en) / Beteiligte

• Nummi, Annu
• Nieminen, Tuomo
• Pätilä, Tommi
• Lampinen, Milla
• Lehtinen, Miia L
• Kivistö, Sari
• Holmström, Miia
• Wilkman, Erika
• Teittinen, Kari
• Laine, Mika
• Sinisalo, Juha
• Kupari, Markku
• Kankuri, Esko
• Juvonen, Tatu
• Vento, Antti
• Suojaranta, Raili
• Harjula, Ari

Titel

Epicardial delivery of autologous atrial appendage micrografts during coronary artery bypass surgery-safety and feasibility study

Ist Teil von

• Pilot and feasibility studies, 2017-12, Vol.3 (1), p.74-74, Article 74

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2017

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The atrial appendages are a tissue reservoir for cardiac stem cells. During on-pump coronary artery bypass graft (CABG) surgery, part of the right atrial appendage can be excised upon insertion of the right atrial cannula of the heart-lung machine. In the operating room, the removed tissue can be easily cut into micrografts for transplantation. This trial aims to assess the safety and feasibility of epicardial transplantation of atrial appendage micrografts in patients undergoing CABG surgery. Autologous cardiac micrografts are made from leftover right atrial appendage during CABG of 6 patients. Atrial appendage is mechanically processed to micrografts consisting of atrial appendage-derived cells (AADCs) and their extracellular matrix (ECM). The micrografts are epicardially transplanted in a fibrin gel and covered with a tissue-engineered ECM sheet. Parameters including echocardiography-reflecting cardiac insufficiency-are studied pre- and post-operatively as well as at 3 and 6 months of the follow-up. Cardiac functional magnetic resonance imaging is performed preoperatively and at 6-month follow-up. The primary outcome measures are patient safety in terms of hemodynamic and cardiac function over time and feasibility of therapy administration in a clinical setting. Secondary outcome measures are left ventricular wall thickness, change in the amount of myocardial scar tissue, changes in left ventricular ejection fraction, plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, New York Heart Association class, days in hospital, and changes in the quality of life. Twenty patients undergoing routine CAGB surgery will be recruited to serve as a control group. This study aims to address the surgical feasibility and patient safety of epicardially delivered atrial appendage micrografts during CABG surgery. Delivery of autologous micrografts and AADCs has potential applications for cell and cell-based gene therapies. ClinicalTrials.gov Identifier: NCT02672163. Date of registration: 02.02.2016.